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operating surgeons after considering indications and contrain-
dications to the use of different groups of drugs (opioid and 
non-opioid analgesics). Postoperative pain was controlled by 
the patient-controlled analgesia method and VRS during the 
day-time, as well as night-time nurse-controlled analgesia. 
All medication adjustments were recorded in the individual 
patient files. In the case of moderate pain intensity (VRS-
assessed), a patient was administered the non-opioid analge-
sic drug, and for high intensity pain the opioid. The analy-
sis of pain relief therapy included information on the drugs 
applied, mode of dosing (single or multiple), daily dose, route 
of administration, and drug refusal due to the absence of 
pain recorded each study day, i.e. on the day of surgery and 
recovery in the postoperative room (day 0), and then daily 
from day 1 to day 6. Polymorphism rs1800795:G>C in the 
promoter region of the IL6 gene (–174G>C) was determined 
using the PCR–RFLP method.
Results The patients carrying at least one IL6 –174G 
allele (GG homozygote and GC heterozygote) were 
administered opioids significantly more often on days 0 
(p = 0.0029), 3 (p = 0.019) and 4 (p = 0.031) after sur-
gery compared with CC homozygous patients. Those 
patients also required a significantly higher opioid dose on 
days 3 (p = 0.029) and 4 (p = 0.030). Multivariate analy-
sis demonstrated that the presence of the –174G allele was 
an independent factor predisposing patients to the admin-
istration of opioids during the first 24 h [p = 0.001, odds 
ratio (OR) 7.1, 95 % confidence interval (CI) 2.17–22.7], 
on day 3 (p = 0.01, OR 2.79, 95 % CI 1.25–6.26) and day 
4 (p = 0.01, OR = 2.61, 95 % CI 1.17–5.79).
Conclusion The presence of the G allele IL6 gene 
(–174G>C) polymorphism was found to be an independ-
ent factor predisposing to a higher dose and more frequent 
administration of opioids in the first days after total hip 
replacement.
Abstract 
Objective In recent years, increasing attention has been 
paid to the contribution of genetic factors to variability in 
patient pain threshold and the efficacy of pain manage-
ment. One of the genes implicated in pain pathology and 
treatment response is interleukin 6 (IL6). The aim of the 
present study was to evaluate the association between IL6 
(rs1800795: –174G>C) and opioid requirements in patients 
after total hip replacement (THR).
Methods A total of 196 patients eligible for the study (126 
women, 70 men) were subjected to THR. The THR procedure 
was performed using spinal anaesthesia after implementing 
routine peri-operative monitoring. After the procedure each 
patient was individually observed, and the patient-specific 
chart of dynamic changes in pain perception was recorded, 
using the five-level Verbal Rating Scale (VRS). The mul-
timodal analgesic treatment after THR was defined by the 
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Introduction
Osteoarthritis (OA) is considered to be the main cause of 
persistent musculoskeletal pain and long-lasting invalidity. 
Hip joint OA is associated with chronic nociceptive pain, 
synthesis of proinflammatory cytokines [e.g. interleukin 
(IL)-1, IL-6, IL-8] and growth factors playing a major role 
in its pathophysiology [1, 2]. The first stage of pain treat-
ment in OA includes non-steroidal anti-inflammatory drugs 
(NSAIDs) and acetaminophen (paracetamol). Alternatively, 
opioid analgesics or intra-articular glucocorticoids are also 
used [3]. Patients with advanced OA require surgical treat-
ment. Regular analgesic treatment after total hip replace-
ment (THR) includes the following drugs: opioids, aceta-
minophen, metamizole and NSAIDs. When these drugs are 
used in multimodal therapy, they produce better analge-
sic responses due to their synergistic actions [4]. Despite 
undeniable progress in pain relief pharmacotherapy, many 
patients do not receive appropriate and effective therapy. In 
recent years, increasing attention has been paid to the con-
tribution of genetic factors to interpatient variability in the 
pain threshold and the efficacy of pain management. One 
of the postulated genes implicated in pain pathology and 
treatment response is interleukin 6 (IL6). The IL-6 protein 
is a multifunctional cytokine that plays an important role in 
a wide range of biological processes. The production and 
concentration of IL-6 can be influenced by the –174G>C 
functional genetic polymorphism in IL6. In vitro studies 
have demonstrated the influence of the polymorphism on 
IL-6 mRNA levels. –174C is associated with lower IL-6 
levels and a reduced response to lipopolysaccharide stim-
ulation. The in vitro findings were paralleled by in vivo 
observations; healthy –174C allele carriers are character-
ized by significantly lower levels of plasma IL-6 [5].
The aim of the present study was to evaluate the asso-
ciation between IL6 (rs1800795: –174G>C) and opioid 
requirements in patients after THR.
Methods
Patients
The analysis of analgesic treatment was conducted in a 
group of 196 patients after THR (126 women, 61.2 %), aged 
from 32 to 86 years (mean 65.1 ± 10.7 years), during the 
planned 7 days of postoperative hospitalization. The mean 
body weight in the study group was 77.01 ± 14.56 kg, and 
the mean body mass index (BMI: kg/m2) was 27.1 ± 4.1. 
Of 196 study participants, 153 were non-smokers (78.1 %) 
and 43 (21.9 %) were smokers. The THR procedures were 
performed by three experienced orthopedic surgeons, via 
a standardized anterolateral approach using the same non-
cemented implant system (Rimcup, Exception, Biomet), 
and medicated according to multimodal therapy in compli-
ance with postsurgical analgesic treatment recommenda-
tions involving oral and/or parenteral analgesics with dif-
ferent mechanisms of action, i.e. opioid analgesics (OP) 
(morphine, pethidine and tramadol), non-opioid analgesics 
(acetaminophen and metamizole) and NSAIDs (ketoprofen 
and diclofenac) [6].
All patients were assessed by a consultant anaesthe-
tist 24 h prior to the operation. To eliminate the impact 
of pharmacological treatment before the surgery on the 
results of the present study, all patients received the same 
type of premedication, 7.5 mg midazolam. Other analge-
sic administrations in 48 h before THR constituted one of 
the exclusion criteria. The THR procedure was performed 
using spinal anaesthesia after implementing routine peri-
operative monitoring. Spinal anaesthesia was performed 
by an experienced consultant anaesthetist, after applying 
local anaesthetic to skin (2–5 ml of 1 % lidocaine), using 
the midline approach, with a pencil-point 27G spinal nee-
dle. After administration of 2–4 ml of 0.5 % heavy bupiv-
acaine (Marcaine Spinal 0.5 % Heavy) without the use of 
any adjuvant, the level of the block was established prior 
to skin incision. The conduct of the spinal anaesthesia was 
recorded in the anaesthetic chart and was performed at the 
discretion of the anaesthetist. After the procedure patients 
were transferred to the postoperative ward and monitored 
according to local protocol. Each patient was individually 
observed, and the patient-specific chart of dynamic changes 
in pain perception was recorded, using the five-level Verbal 
Rating Scale (VRS). All patients, in the timeframe of 3–6 h 
after the surgery, were intravenously administered one of 
two (based on drug-related indications and contraindica-
tions) non-opioid analgesics, viz. 1.0 g metamizole or 1.0 g 
acetaminophen, as recommended by the Polish Association 
for the Study of Pain [7]. Patients were transferred to the 
orthopaedic ward immediately after successful pain con-
trol, i.e. no pain or mild pain assessed by VRS. The mul-
timodal analgesic treatment after THR was defined by the 
operating surgeons after considering indications and con-
traindications to the use of the two groups of drugs (opioid 
and non-opioid analgesics). Postoperative pain was con-
trolled by the patient-controlled analgesia (PCA) method 
and VRS during day-time, as well as night-time nurse-con-
trolled analgesia (NCA). The pain intensity was recorded 
several times a day by a managing physician (at least dur-
ing morning and evening check visits) or night-shift phy-
sician, complemented by recorded patients’ claims of 
increased pain intensity. In our study, rehabilitation started 
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on the day of surgery, after discharge from the recovery 
room. To assess pain intensity, the five-level (VRS) was 
used, where a score of 3–4 was classified as a moderate 
intensity of pain, and score 5 as severe pain. The selection 
of opioids and non-opioids was based on the VRS score. 
In the case of moderate pain intensity (VRS 3–4), a patient 
was administered a non-opioid analgesic drug, and for 
high-intensity pain an opioid. All medication adjustments 
were recorded in the individual patient files. The dose of 
injectable opioids was converted to injectable morphine 
dose according to the conversion factors given in the litera-
ture: tramadol 10:1 and pethidine 10:1 [8]. For analysis of 
non-opioid and/or NSAID use, the 0/1 system was applied. 
The term 1 indicates a day on which non-opioids and/or 
NSAIDs were taken, whereas a day without medication 
with those drugs was described as 0. The simplified system 
was applied, since different drugs were administered (keto-
profen, diclofenac, acetaminophen, metamizole) and no 
reliable data is available to date for dose equivalence cal-
culations. The above-mentioned medications were adminis-
tered parenterally (opioids) or orally (non-opioid analgesics 
and NSAIDs). The analysis of pain relief therapy included 
information on the drugs applied, mode of dosing (single 
or multiple), daily dose, route of administration, and drug 
refusal due to the absence of pain recorded each study day. 
i.e. on the day of surgery and recovery in postoperative 
room (day 0), and then daily from day 1 to day 6. The pro-
tocol of the study was approved by the Ethics Committee 
at Pomeranian Medical University (BN-001/6/07), and all 
patients gave written informed consent.
Genetic analysis
Genomic DNA was extracted from 200 μL of whole blood 
samples using Gene-MATRIX Quick Blood DNA Purifica-
tion Kit (EURx, Poland). Polymorphism rs1800795:G>C 
in the promoter region of the IL6 gene (–174G>C) was 
determined using the PCR–RFLP method, as described 
previously [9], with minor modifications. Briefly, a 299-
bp fragment of the IL6 gene was amplified during 35 
cycles of PCR (initial denaturation at 95° for 5 min, then 
95 °C/59 °C/72 °C, each step for 30 s) with the primer 
pair: sense primer: 5′-TGT CAA GAC ATG CCA AGT 
GCT-3′ and antisense: 5′-GCC TCA GAG ACA TCT CCA 
GT CC-3′. Amplification reactions were performed in a 
total volume of 12 μL using Mastercycler ep Gradient S 
(Eppendorf, Germany). The amplification mix contained 
0.3 pmol/μL of each primer, 20 ng of genomic DNA, 
0.6 U of RedTaq Polymerase (Sigma-Aldrich, Germany) 
in 1× enzyme-specific buffer (containing magnesium 
chloride at a final concentration of 1.5 mMol) and deoxy-
nucleoside triphosphates (Sigma-Aldrich), 200 μmol of 
each. Subsequently, the PCR product was digested with 
Hin1II endonuclease (ThermoFisher Scientific, Lithu-
ania) at 37 °C and separated on a 4 % agarose gel to dis-
tinguish between allele G (227 + 50 + 13 bp) and allele C 
(118 + 109 + 50 + 13 bp).
Statistical analysis
The Mann–Whitney test was used to compare opioid doses 
between genotype groups. The χ2 test and Fisher exact 
test were used to analyze associations between genotypes 
or alleles and administration of opioids. Multiple logistic 
regression was performed to find independent variables 
associated with the administration of opioids. p < 0.05 was 
considered significant. Statistica 10 was used for statistical 
calculations.
Results
The analysis of analgesic treatment revealed that 179 
patients (91.33 %) required administration of opioids as a 
multimodal post-surgical analgesia on the day of the sur-
gery. Opioids were not administered in 17 patients (8.67 %) 
due to a lack of pain, based on the verbal rating scale 
(VRS). The number of patients who continued opioid-
based treatment in the subsequent days of hospitalization 
gradually decreased to 143 (72.95 %), 125 (63.77 %), 102 
(52.04 %) and 59 (30.10 %) patients in the third, fourth, 
fifth and sixth day of treatment, respectively. Table 1 pro-
vides the mean doses (per kg of body weight) of opioids 
used on days 0–6, revealing a gradual reduction in demand 
for daily doses of opioids in the days following sur-
gery. During the 7 days of hospitalization, 172 (87.75 %) 
received NSAIDs and 144 (73.46 %) were administered 
paracetamol.
Thirty-four patients were carriers of the IL6CC genotype 
(17.35 %), 93 patients (47.45 %) were heterozygous, and 
69 (35.20 %) patients were carriers of the GG genotype. 
The distribution of IL6 genotypes was in agreement with 
Hardy–Weinberg equilibrium (HWE p = 0.77). IL6CC 
Table 1  Opioid dose in the days following surgery
bw body weight
Day Mean ± SD (mg/kg bw)
0 0.17 ± 0.10
1 0.21 ± 0.14
2 0.16 ± 0.12
3 0.14 ± 0.12
4 0.13 ± 0.13
5 0.08 ± 0.11
6 0.05 ± 0.09
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homozygotes required a significantly lower opioid dose 
(per kg body weight) compared to GC + GG on day 3 
(p = 0.029) and 4 (p = 0.030) (Table 2).
Table 3 presents the results of investigation on the poten-
tial association between IL6 genotype and absence of opioid 
administration. The patients carrying at least one G allele (GG 
homozygote and GC heterozygote) were administered opioids 
significantly more often on days 0, 3 and 4 compared with 
CC homozygous patients. The frequency of the G allele was 
higher among patients who required opioid administration, but 
the difference did not reach statistical significance (Table 3).
Multivariate logistic regression analysis was performed, 
with age, sex, BMI, tobacco smoking status, NSAIDs, 
acetaminophen, and the –174G allele as the independent 
variables. The analysis demonstrated that the presence of 
the –174G allele was an independent factor predisposing 
patients to administration of opioids during the first 24 h 
[p = 0.001, odds ratio (OR) 7.1, 95 % confidence interval 
(CI) 2.17–22.7], on day 3 (p = 0.01, OR 2.79, 95 % CI 
1.25–6.26) and day 4 (p = 0.01, OR 2.61, 95 % CI 1.17–
5.79) after THR. In the same multivariate analysis, admin-
istration of NSAIDs significantly influenced the need for 
opioid analgesics only in the first 24 h of the postoperative 
period (the day 0, p = 0.02).
Table 2  Association of the IL6 –174 gene polymorphism with opioid 
dose
Bold type indicates significantly different at p < 0.05
bw Body weight 
* Mann–Whitney test
Day IL6 –174G>C genotype CC vs GC + GG
GG (n = 69) GC (n = 93) CC (n = 34)
Mean ± SD (mg/kg bw) p*
0 0.17 ± 0.10 0.18 ± 0.09 0.15 ± 0.13 0.160
1 0.19 ± 0.13 0.23 ± 0.14 0.20 ± 0.13 0.600
2 0.16 ± 0.13 0.17 ± 0.12 0.15 ± 0.12 0.600
3 0.14 ± 0.12 0.15 ± 0.11 0.10 ± 0.11 0.029
4 0.13 ± 0.13 0.13 ± 0.13 0.09 ± 0.12 0.030
5 0.07 ± 0.11 0.10 ± 0.11 0.06 ± 0.08 0.410
6 0.04 ± 0.09 0.06 ± 0.10 0.03 ± 0.06 0.320
Table 3  Comparison of IL6 
genotype and allele distribution 
in patients stratified by the need 
for opioid administration
Bold type indicates significantly different at p < 0.05
OR odds ratio; CI confidence interval
a  χ2 test; b Fisher exact test







p valuea p valueb OR (95 % CI)
n % n %
0 Genotype
 CC 8 47.06 26 14.52 0.0015 GG + GC vs CC 0.0029 5.23 (1.85–14.79)
 GC 3 17.65 90 50.28 GG vs GC + CC 1.000 1.00 (0.35–2.82)
 GG 6 35.29 63 35.20 GG vs CC 0.063 3.23 (1.02–10.23)
Allele
 G 15 44.12 216 60.34
 C 19 55.88 142 39.66 G vs C 0.071 1.93 (0.95–3.92)
3 Genotype
 CC 15 28.30 19 13.29 0.039 GG + GC vs CC 0.019 2.58 (1.19–5.55)
 GC 20 37.74 73 51.05 GG vs GC + CC 0.870 1.08 (0.56–2.09)
 GG 18 33.96 51 35.66 GG vs CC 0.076 2.24 (0.94–5.31)
Allele
 G 56 52.83 175 61.19
 C 50 47.17 111 38.81 G vs C 0.170 1.41 (0.90–2.21)
4 Genotype
 CC 18 25.35 16 12.80 0.074 GG + GC vs CC 0.031 2.31 (1.09–4.89)
 GC 29 40.85 64 51.20 GG vs GC + CC 0.880 1.10 (0.60–2.03)
 GG 24 33.80 45 36.00 GG vs CC 0.091 2.11 (0.91–4.87)
Allele
 G 77 54.23 154 61.60
 C 65 45.77 96 38.40 G vs C 0.170 1.35 (0.89–2.05)
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Discussion
Total hip replacement involves trauma to soft and bony tis-
sues, and can result in considerable pain. It is worth noting 
that the greater the amount of tissue injury, the more active 
the inflammation that can occur in the perisurgical region. 
After tissue injury, a proinflammatory cytokine, IL-6, is 
overproduced by many cells throughout the body [10, 11]. 
Higher IL-6 concentrations trigger synthesis of acute phase 
proteins such as CRP, and activation of the innate immune 
system [12]. Since the IL6 –174G allele is associated with 
increased gene expression, it may lead to even higher IL-6 
levels in the allele carriers, resulting in increased inflamma-
tion and, as a consequence, greater stimulation of nocicep-
tors by mediators generated in the inflammatory zone. The 
results of the current study are consistent with that hypoth-
esis, as the presence of the G allele predisposed patients to 
higher demands for analgesics, i.e. opioid requirements in 
the early postoperative period.
This observation is contrary to the results of Reyes-
Gibby et al. [13], who reported that lung cancer patients 
with the IL6 –174CC genotype required significantly 
higher daily opioid doses than carriers of the G allele. How-
ever, the aforementioned study involved patients on previ-
ous opioid medication and with chronic pain, contrary to 
our study. Unfortunately, the current study did not involve 
measurements of IL-6 concentrations. However, it was 
previously demonstrated that the IL-6 level increases after 
THR, and the peak concentrations after operation occur 
at 12–24 h [11]. Considering the above-mentioned obser-
vations, it may be assumed that IL-6 concentrations were 
highest on the first day after the surgery. The IL6 –174GG 
genotype patients could be characterized by higher IL-6 
levels compared with CC carriers, with resultant increased 
demands for opioids within 24 h of the surgery. The obser-
vation of the present study indicated that morphine doses 
and pain intensity gradually decreased during the postop-
erative period, but a subgroup of patients still suffered from 
pain of significant intensity. The patients carrying at least 
one IL6 –174G allele (GG homozygote and GC heterozy-
gote) were administered opioids significantly more often, 
also on days 3 and 4, compared with CC homozygous 
subjects. One possible explanation may be derived from 
in vitro studies, which demonstrated peripheral actions of 
opioids such as modulation of inflammatory processes and 
wound healing [14]. Opioids can interfere with different 
stages in the inflammatory cascade evoked by tissue injury, 
trauma or infection, mitigating the inflammation. However, 
adding those findings to the results of the present study, we 
may assume that patients predisposed by genetic factors 
(determined by IL6 –174G>C polymorphism) are charac-
terized by elevated levels of IL-6, and thus require a more 
intensive analgesic approach in the early postoperative 
period. It is known that IL-6 levels decrease gradually after 
surgical procedures [11, 15], as IL-6 production is primar-
ily regulated by a negative feedback mechanism through 
suppressors of cytokine signaling molecules, coded by 
genes of the Janus kinase and signal transducer and acti-
vator of transcription (JAK-STAT) pathway. This, in turn, 
reduces overproduction of IL-6 after injury.
Our study also demonstrated that administration of 
NSAIDs significantly influenced the need for opioid anal-
gesics within the first 24 h of the postoperative period. 
This observation is in keeping with the report of Slattery 
et al. [16], who demonstrated correlation between the 
analgesic effects of acetylsalicylic acid and IL6 genotype 
in breast cancer patients. Acetylsalicylic acid effects were 
most potent in female carriers of the wild-type IL6 –174G 
allele, which was associated with constitutively high IL-6 
levels. It is worth noting that in the multivariate logistic 
regression analysis the presence of the –174G allele was 
an independent factor predisposing patients to administra-
tion of opioids during the first 24  and, on days 3 and 4 
after THR.
The results of the present study may be biased by some 
confounding factors, especially by factors other than 
genetic ones which can affect the circulating IL-6 concen-
trations (e.g. other cytokines that have been shown to mod-
ulate pain), and gene polymorphisms of other pain modula-
tors, not assessed in this study. Because of the complexity 
of pain pathology and inflammatory responses, most likely 
combinations of multiple polymorphisms would be ade-
quate as predictors of analgesia.
Conclusion
The IL6 (rs1800795: G>C) –174 gene polymorphism has 
a significant influence on the overall requirement and daily 
doses of opioids in patients after elective THR.
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